ERBB2 and breast cancer: The HER-2-low subtype was first described in breast cancer, where this group—characterized by limited sensitivity to conventional HER-2-targeted therapies—was shown to be responsive to novel antibody–drug conjugates, such as trastuzumab deruxtecan [7].